Population Pharmacokinetics of Linezolid

Overview

Linezolid is the first of a new class of antibacterial drugs, the oxazolidinones. It has a specific inhibitory activity against Gram positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Dosage of 600 mg discontinuous administration twice a day was about studies in safety volunteers. The intensive care units patients, with mechanical ventilation, and with severe sepsis, represent highly heterogeneous population responsible of hight variability in pharmacokinetics parameters (augmentation in total volume of distribution, modification in glomerular filtration) wich can lead to antibiotic inefficacy. In a first time, this study describe the pharmacokinetics of Linezolid in intensive care units patients with severe MRSA infection. The aim of this study is to define and validate a population pharmacokinetic model including the influence of patients' characteristic on the pharmacokinetics of Linezolid.

Full Title of Study: “Population Pharmacokinetics of Linezolid in Intensive Care Units Patients Treated for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2010

Detailed Description

The demographic, clinical and biological parameters are collected. Patients receive Linezolid as 600 mg twice a day during an administration of 60 minutes. Blood sampling are collected on the second day after beginning of treatment at the following time : H1, H2, H3, H6 and H12. The population pharmacokinétics analysis will be carried out using Monolix, a software for the analysis of nonlinear mixed effects models.

Interventions

  • Drug: Linezolid
    • Dosage of 600 mg discontinuous administration twice a day was about studies in safety volunteers

Arms, Groups and Cohorts

  • Experimental: MRSA Infections
    • Methicillin-Resistant Staphylococcus aureus Infections

Clinical Trial Outcome Measures

Primary Measures

  • The first objective of this study is to research the influence of patients’ characteristic on the pharmacokinetics of Linezolid.
    • Time Frame: Blood sampling are collected on the second day after begining of treatment at the following time : H1, H2, H3, H6 and H12.
    • The following demographic, clinical and biological parameters were collected as possible covariates: age, gender, bodyweight, height, etiology of incoming, mechanical ventilation, serum creatinine, proteins, Blood Urea Nitrogen (BUN), leukocyte counts, haemoglobin, C-reactive protein (CRP), and simplified acute physiology scores (SAPS I and II).

Secondary Measures

  • The secondary outcome measure are the verification of the clinical and bactériological efficacies, and to look after the residual concentration
    • Time Frame: At the 48th hours of treatment

Participating in This Clinical Trial

Inclusion Criteria

  • In-patient stay in intensive care – Over 18 years old – Presenting with MRSA nosocomial pneumonia or bacteraemia with a strain thought to be sensitive to Linezolid – Simplified Acute Physiological Score (SAPS) II > 20 – Expected duration of life > 7 days. Exclusion Criteria:

  • History of allergy to linezolid or any of the antibiotics used – Isolation of MRSA resistant to linezolid – Lack of seeds – Pregnancy and lactation

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Toulouse
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Bernard Georges, PhMD, Principal Investigator, UH Toulouse

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.